Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aripiprazole + risperidone is a combination of two second-generation (atypical) antipsychotics, aripiprazole and risperidone, both commonly used for treating psychiatric disorders such as schizophrenia and bipolar disorder. Aripiprazole functions primarily as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, as well as an antagonist at serotonin 5-HT2A receptors, exerting a dopamine stabilizing effect. Risperidone acts mainly as an antagonist at dopamine D2 receptors and serotonin 5-HT2A receptors, and is also known to antagonize norepinephrine alpha-2 receptors. These complementary mechanisms target dopaminergic and serotonergic neurotransmission to correct imbalances associated with psychosis and mood disorders. Combination therapy may be considered for refractory cases, with the main risks being additive side effects, especially metabolic changes[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aripiprazole + risperidone.